Novo Holdings participates in €23 million Series A for Tribune Therapeutics to advance next-generation anti-fibrotic therapies
- Investment addresses the need for disease-modifying therapies targeting the root causes of fibrosis
- Funding will support the advancement of CCN family inhibitor TRX-44 into clinical trials for treatment of fibrotic conditions including idiopathic pulmonary fibrosis (IPF)
- Novo Holdings and HealthCap co-created Tribune in 2020
COPENHAGEN – March 24th, 2025 – Novo Holdings today announced its participation in a €23 million Series A round for Tribune Therapeutics (‘Tribune’). The round was led by new investor LifeArc Ventures and joined by Novo Holdings, HealthCap, Innovestor’s Life Science Fund and Inven2 as well as new Series A investors Industrifonden and Investinor.
